Skip to main content

Table 2 Univariate analysis of clinical pathology and prognosis of 2917 BC patients with bone metastasis

From: Impact of surgery on survival in breast cancer with bone metastases only: a SEER database retrospective analysis

Variables Number Median survival time (month) 95% confidence interval (CI) χ2 P-value
Race      
White 2255 44 41.617–46.383 35.071  < 0.001
Black 462 31 27.607–34.393   
Other 200 43 31.973–54.027   
Grade      
1 287 46 37.721–54.279   
2 1440 46 42.998–49.002 45.128  < 0.001
3–4 1190 34 31.198–37.002   
Marital      
Married 1416 48 44.517–51.483 45.771  < 0.001
Unmarried 1501 36 33.209–38.791   
Age      
 ≤ 35 134 56 38.548–73.452   
35 < age < 60 1345 46 42.387–49.613 70.468  < 0.001
 ≥ 60 1438 36 33.066–38.934   
Ethnic origin      
Spanish-Hispanic-Latino 289 47 41.597–52.403 2.103 0.147
Non-Spanish-Hispanic-Latino 2628 41 38.983–43.017   
Laterality      
Left 1525 42 39.446–44.554 0.017 0.896
Right 1392 42 39.085–44.915   
Histology      
IDC 2351 44 41.537–46.463 25.295  < 0.001
Non-IDC 566 36 32.245–39.755   
T stage      
T1 383 47 38.824–55.176   
T2 1158 47 42.855–51.145 53.468  < 0.001
T3 553 40 35.692–44.308   
T4 823 34 30.984–37.016   
N stage      
N0 704 39 34.668–43.332   
N1 1326 43 39.941–46.059 5.582 0.134
N2 406 43 37.639–48.361   
N3 481 42 38.004–45.996   
Radiation      
Yes 1302 46 42.593–49.407 14.906  < 0.001
No 1615 39 36.512–41.488   
Chemotherapy      
Yes 1564 48 44.242–51.758 64.579  < 0.001
No 1353 36 33.254–38.746   
Subtype      
ER + /HER2− 2114 43 41.030–44.970   
ER + /HER2 +  433 57 48.725–65.275 242.199  < 0.001
HER2 +  122 73 0   
TNBC 248 13 11.349–14.651   
ER      
Positive 2532 44 42.077–45.923 91.338  < 0.001
Negative 385 18 14.319–21.681   
PR      
Positive 2121 46 43.765–48.235 97.923  < 0.001
Negative 796 27 23.973–30.027   
HER2      
Positive 555 58 46.618–69.382 30.843  < 0.001
Negative 2362 40 37.931–42.069   
Primary surgery      
Operation 1245 56 51.508–60.492 146.023  < 0.001
Non-operation 1672 33 30.830–35.170   
Surgical mode      
Non-operation 1672 33 30.830–35.170   
BCS 381 70 0 157.117  < 0.001
Mastectomy 255 59 45.751–72.249   
Radical mastectomy 609 48 43.369–52.631   
  1. ER estrogen receptor, PR progesterone receptor, Her-2 human epidermal growth factor receptor 2, IDC infiltrating ductal carcinoma, BCS breast conserving surgery, TNBC triple-negative breast cancer
Back to article page

BMC Surgery

ISSN: 1471-2482

Contact us